(Q39107424)

9 September 2017

title

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling (English)

1 reference

9 September 2017

Cristina Caffarra

2

0 references

Andrea Cavazzoni

Andrea Cavazzoni

6

0 references

Daniele Generali

Daniele Generali

8

0 references

Maricla Galetti

4

Maricla Galetti

1 reference

9 September 2017

1

Claudia Fumarola

1 reference

9 September 2017

3

Silvia La Monica

1 reference

9 September 2017

7

Elena Galvani

1 reference

9 September 2017

10

Mara A Bonelli

1 reference

9 September 2017

Pier Giorgio Petronini

9

Pier Giorgio Petronini

1 reference

9 September 2017

Roberta R Alfieri

5

1 reference

9 September 2017

language of work or name

English

0 references

publication date

21 August 2013

1 reference

Breast Cancer Research and Treatment

9 September 2017

published in

1 reference

9 September 2017

volume

141

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

67-78

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-013-2668-x

9 September 2017

exact match

0 references

cites work

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib for the treatment of unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Synergistic activity of letrozole and sorafenib on breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Mechanisms and methods in glucose metabolism and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

The pentose cycle and insulin release in mouse pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Molecular mechanisms of sorafenib action in liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Redox implications of AMPK-mediated signal transduction beyond energetic clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Glucose metabolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2668-X

10.1007/S10549-013-2668-X

21 January 2018

Identifiers

DOI

1 reference

release_7qus4atnhffgdlkvhvb4tg3xu4

9 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7qus4atnhffgdlkvhvb4tg3xu4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference